
WHAT IS CLAIMED IS:

1. Use of a compound having a structure:



wherein each dashed line represents the presence or absence of a double bond;

R^1, R^2, R^3 and R^4 are each independently selected from H and C_1-C_6 linear alkyl;


R^5 is halogen, C_1-C_6 alkyl, or C_1-C_6 alkenyl; R^6 is H, C_1-C_6 alkyl, C_1-C_6 alkenyl, a salt thereof, or an amine thereof; n is 0-7; and X is S or O, in the manufacture of a medicament for treating a skin blemish, wherein the skin blemish is a flesh wound or scar.

2. The use of claim 1 , wherein R^4 is H, R^3 is H, and X is S.

3. The use of claim 1 , wherein R^1 and R^2 are CH_3.

4. The use of claim 1 , wherein R^5 is Cl.

5. The use of claim 1 , wherein the compound is:



~~6. The use of claim 1, wherein the skin blemish is a flesh wound, scar, or wrinkle.~~

~~7~~6. The use of claim 1, wherein the medicament is to be administered subcutaneous, subdermal or transdermal, intradermally or topically.

~~8~~7. The use of claim ~~6~~1, wherein the administration reduces formation of a scar type selected from the group consisting of hypertrophic scar, recessed scar, stretch mark, and a combination thereof.

~~9. The use of claim 6, wherein the skin blemish is a wrinkle.~~

~~10~~8. The use of claim 1, wherein the medicament is to be administered to a region selected from the group consisting of a face, neck, arms, torso, back, legs, and a combination thereof.

~~11~~9. The use of claim 1~~-~~, wherein the medicament is to be administered at a time selected from the group consisting of prior to surgical incision, during surgery, post-operatively, and a combination thereof.

~~12~~10. The use of claim 1, wherein administration of said medicament minimizes scar formation.

~~13~~11. The use of claim 1, wherein administration of said medicament prevents scar formation.


~~14. The use of claim 1, wherein administration of said medicament prevents wrinkle formation.~~

~~15. The use of claim 1, wherein administration of said medicament reduces the appearance of an existing wrinkle.~~

~~16. The use of claim 9, wherein the wrinkle is selected from the group consisting of a brow furrow, crows feet, nasolabial fold, a line under the eye, a crease between the eye brows, and a combination thereof.~~

~~17~~12. The use of claim ~~6~~1, wherein a cause of said flesh wound is selected from the group consisting of an incision, a laceration, a thermal burn, a chemical burn, an abrasion, a puncture wound, and a combination thereof.

~~18~~13. Use of a compound having a structure:




wherein each dashed line represents the presence or absence of a double bond;

R^1, R^2, R^3 and R^4 are each independently selected from H and C_1-C_6 linear alkyl;


R^5 is halogen, C_1-C_6 alkyl, or C_1-C_6 alkenyl; R^6 is H, C_1-C_6 alkyl, C_1-C_6 alkenyl, a salt thereof, or an amine thereof; n is 0-7; and X is S or O, in the manufacture of a medicament for treating a flesh wound,

wherein said wound heals more normally than without administration of said composition.

~~19~~14. The use of claim ~~18~~13, wherein the compound is Compound 1 :



~~20~~15. ~~Use of a compound having structure~~ A method of reducing the appearance of a wrinkle comprising administering to said wrinkle a composition comprising a therapeutically effective amount of a compound having a structure:




wherein each dashed line represents the presence or absence of a double bond;

R^1, R^2, R^3 and R^4 are each independently selected from H and C_1-C_6 linear alkyl;

R^5 is halogen, C_1-C_6 alkyl, or C_1-C_6 alkenyl; R^6 is H, C_1-C_6 alkyl, C_1-C_6 alkenyl, a thereof, or an amine thereof; n is 0-7; and X is S or O, ~~in the manufacture of a medicament for reducing the appearance of a wrinkle~~wherein the appearance of said wrinkle is diminished.

~~21~~16. The ~~use~~ method of claim ~~20~~15, wherein the compound is:



~~22~~17. The ~~use~~ method of claim ~~20~~15, wherein said ~~medicament~~ composition is ~~to be~~ administered topically.

18. The method of claim 15, wherein R^4 is H, R^3 is H, and X is S.

19. The method of claim 15, wherein R^1 and R^2 are CH_3.

20. The method of claim 15, wherein R^5 is Cl.

21. The method of claim 15, wherein the composition is administered subcutaneous, subdermal or transdermal, intradermally or topically.

22. The method of claim 15, wherein the composition is administered to a region selected from the group consisting of a face, neck, arms, torso, back, legs, and a combination thereof.

23. The method of claim 15, wherein the composition is administered at a time selected from the group consisting of prior to surgical incision, during surgery, post-operatively, and a combination thereof.

24. The method of claim 15, wherein said administration prevents wrinkle formation.

25. The method of claim 15, wherein said administration reduces the appearance of an existing wrinkle.

26. The method of claim 25, wherein the wrinkle selected from the group consisting of a brow furrow, crows feet, nasolabial fold, a line under the eye, a crease between the eye brows, and a combination thereof.